Breaking down access barriers for antibiotics: Cefiderocol as a pathfinder



This webinar presented the cefiderocol access project and addressed issues around antibiotic access more broadly.

Nearly 1.3 million people die every year from antibiotic resistance. We know that the overuse and misuse of antibiotics in humans and animals contribute to this problem, but so does lack of access to antibiotics.

As part of its efforts to counter antibiotic resistance, the Global Antibiotic Research and Development Partnership (GARDP) is working to find innovative solutions to rapidly expand access to antibiotics for appropriate use. The cefiderocol access project—which involves an innovative license agreement between Shionogi and GARDP, and a collaboration agreement between Shionogi, GARDP, and the Clinton Health Access Initiative (CHAI)—has been called a “pioneering model for access through partnership” and a “first-in-kind approach”.


  • Jennifer Cohn – Global Access Project Leader, GARDP
  • Gareth Morgan – Head of Global Portfolio Management, Shionogi, Inc. (USA)
  • David RipinExecutive Vice President of Infectious Diseases & Chief Scientific Officer, CHAI
  • Kamini Walia – Senior Scientist and Program Officer of AMR, Indian Council of Medical Research
  • Mirfin Mpundu Director ReAct Africa
  • Jeremy Knox Head of Policy, Infectious Disease, Wellcome Trust
  • Claire Doole Moderator

Find out more about GARDP’s work on antibiotic access: